| [¹⁴C] Hydronidone Mass Balance Study (NCT07471217) | Beijing Continent Pharmaceutical Co, Ltd. | 2026-04-30 |
| A Study of Hydronidone Capsules in Patients With Chronic Hepatitis B Virus-Related Liver Fibrosis (NCT07417553) | Beijing Continent Pharmaceutical Co, Ltd. | 2026-04-15 |
| Study of Hydroxynidone Capsules in Patients With Hepatic Impairment and Matched Healthy Controls (NCT07394309) | Beijing Continent Pharmaceutical Co, Ltd. | 2026-03-25 |
| A Clinical Trial Evaluating the Safety of Hydronidone Capsules in Patients With Hepatic Fibrosis and Liver Cirrhosis (NCT07343778) | Beijing Continent Pharmaceutical Co, Ltd. | 2026-03-16 |
| Drug-Drug Interaction Study Between Hydronidone and Entecavir, Tenofovir Disoproxil Fumarate, Tenofovir Alafenamide, and Tenofovir Amibufenamide (NCT07295873) | Beijing Continent Pharmaceutical Co, Ltd. | 2026-03-15 |
| A Study to Evaluate the Safety of Hydronidone Capsules in Patients With Liver Fibrosis (NCT07364448) | Beijing Continent Pharmaceutical Co, Ltd. | 2026-03-12 |
| A Phase IIIc Clinical Study to Evaluate the Long-term Treatment of Hydronidone Capsules for Liver Fibrosis in Patients With Chronic Hepatitis B. (NCT07412236) | Beijing Continent Pharmaceutical Co, Ltd. | 2026-01-30 |
| QTc Assessment in a Single-Dose Study of Hydronidone Capsules (NCT07263152) | Beijing Continent Pharmaceutical Co, Ltd. | 2025-12-30 |
| A Trial of Hydroxynidone Capsules in Single-dose Administration for Patients With Renal Insufficiency (NCT07262333) | Beijing Continent Pharmaceutical Co, Ltd. | 2025-12-25 |
| The Phase Ⅰd Clinical Trial of Hydronidone Capsules (NCT07262346) | Beijing Continent Pharmaceutical Co, Ltd. | 2025-12-05 |
| Preliminary Human Trials of F230 Tablets (NCT06899815) | Beijing Continent Pharmaceutical Co, Ltd. | 2025-05-15 |
| Hydronidone Capsules in Long-term Treatment in Patients With Chronic Viral Hepatitis B Liver Fibrosis (NCT05905172) | Beijing Continent Pharmaceutical Co, Ltd. | 2023-08-12 |
| F573 for Injection for the Treatment of Liver Injury/Failure (NCT05689645) | Beijing Continent Pharmaceutical Co, Ltd. | 2023-03-24 |
| Efficacy and Safety of Pirfenidone Capsules in the Treatment of Pneumoconiosis (NCT05288179) | Beijing Continent Pharmaceutical Co, Ltd. | 2022-06-07 |
| F573 Ia Clinical Trial (NCT04820049) | Beijing Continent Pharmaceutical Co, Ltd. | 2021-02-08 |
| Study on Pharmacokinetics of Hydronidone (NCT04162821) | Beijing Continent Pharmaceutical Co, Ltd. | 2019-10-30 |
| Study on PK of Hydronidone in Patients and Special Population (NCT04123769) | Beijing Continent Pharmaceutical Co, Ltd. | 2019-09-03 |
| Pirfenidone Capsule in Patients With Chronic Kidney Disease G2 and G3a Study on Safety and Pharmacokinetics (NCT04126538) | Beijing Continent Pharmaceutical Co, Ltd. | 2019-08-27 |
| A Study About Safety and Efficacy of Pirfenidone to Treat Grade 2 or Grade3 Radiation-induced Lung Injury. (NCT03902509) | Beijing Continent Pharmaceutical Co, Ltd. | 2019-05-24 |
| Pharmacokinetic Interactions Between Hydronidone and Entecavir Capsules in Healthy Chinese Subjects (NCT04124081) | Beijing Continent Pharmaceutical Co, Ltd. | 2019-05-15 |
| Study on Hydronidone Capsule BE (NCT04125056) | Beijing Continent Pharmaceutical Co, Ltd. | 2019-01-16 |
| Efficacy and Safety of Pirfenidone in Patient With Systemic Sclerosis-associated Interstitial Lung Disease (NCT03856853) | Beijing Continent Pharmaceutical Co, Ltd. | 2018-06-15 |
| Efficacy and Safety of Pirfenidone in Patient With Dermatomyositis Interstitial Lung Disease (Dm-ILD) (NCT03857854) | Beijing Continent Pharmaceutical Co, Ltd. | 2018-06-05 |